Which patients with COPD could benefit from Trelegy Ellipta?

Patients with COPD who are symptomatic and at risk of an exacerbation despite dual maintenance therapy may be suitable for Trelegy Ellipta.1

How can Trelegy Ellipta help your patients with COPD who are symptomatic and at risk of an exacerbation?

Watch how Trelegy Ellipta compared against dual maintenance therapy in terms of exacerbation reduction, lung function and health-related quality of life.

How to identify patients with COPD who are symptomatic and at risk of exacerbation despite dual maintenance therapy

Patients with COPD who are symptomatic and at risk of exacerbation can be difficult to identify. How can you uncover more when they tell you they "feel fine"?

The consequences for patients who are symptomatic and at risk of exacerbation despite dual maintenance therapy

Even a single exacerbation can be associated with poorer outcomes2-4. What can you do for these at-risk patients?

Fictional patient with COPD

For patients with COPD like Sylvia, ICS/LABA may not be enough

Sylvia is on treatment with a dual maintenance therapy, symptomatic and at risk of an exacerbation:

  • Has worsening of symptoms, or
  • Has experienced an exacerbation treated with antibiotics or oral corticosteroid, in the past 12 months

How is COPD impacting her life?

  • Starting to miss social events with friends
  • Struggles to keep her small garden tidy
  • Difficulty walking to the shops
  • Can’t keep up when playing with young grandchildren

It is important to reduce exacerbations. Even a single exacerbation can be associated with poorer outcomes for patients with COPD2-4

Effect on lung function

~37% faster decline in lung function vs. no exacerbation*2
 

 Risk of heart attack

2x increased risk of myocardial infarction in 1–5 days after exacerbation**3

Risk of death

~50% risk of death within 5 years following a hospitalised exacerbation4

*Post hoc analysis of the 3-year Toward a Revolution in COPD Health (TORCH) study in patients with moderate or severe COPD (treatment arms: salmeterol 50 mcg, fluticasone propionate 500 mcg, salmeterol/fluticasone propionate 50/500 mcg or placebo, all twice daily). The primary endpoint of the study did not reach statistical significance. Data shown compares patients with >0-1 moderate /severe exacerbations per annum vs. 0 exacerbations per annum. Analysis includes patients on active treatment and placebo.

Seretide (fluticasone propionate/salmeterol xinafoate) is indicated for the symptomatic treatment of patients with COPD, with a FEV1 <60% predicted normal (pre-bronchodilator) and a history of repeated exacerbations, who have significant symptoms despite regular bronchodilator therapy.5 Seretide prescribing information.

**There was a 2.27 fold (95%CI, 1.1-4.7; p=0.03) increased relative risk of MI 1 to 5 days after exacerbation (defined by prescription of both steroids and antibiotics). There were 20,101 exacerbations and 8 MI events in the 1-5 day post exacerbation period, so the odds of an MI were 1 in 2513 exacerbations. The Health Improvement Network (THIN) database study: 25,857 patients with COPD in 277 practices from THIN database, 25 February 2003 – 24 February 2005

Footnotes

ICS, inhaled corticosteroid; LABA, long-acting ß₂-agonist; LAMA, long-acting muscarinic antagonist; MI, myocardial infarction; QoL, quality of life

Trelegy Ellipta OD is indicated for maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting β2-agonist or a combination of a long-acting β₂-agonist and a long-acting muscarinic antagonist.1

References

  1. Trelegy SmPC
  2. Celli B et al. Am J Respir Crit Care Med 2008; 178:332-338 (see table 5, p.336)
  3. Donaldson GC et al. Chest 2010; 137:1091-1097
  4. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease (GOLD) 2020 pages 30 and 105.
  5. Seretide Accuhaler SmPC

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App Store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441

© 2021 GSK Group of Companies or its licensor
Trademarks are the property of their respective owners
Trelegy Ellipta was developed in collaboration with

PM-GB-FVU-WCNT-200012 | August 2021